Pathology Network Selected Publications

  • Abutalib SA, Wetzler M, Stock W. Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. Hematology/oncology clinics of North America 2009; 235:1099-1119
  • Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010; 28(4):614-9. PMCID: PMC2815996
  • Akakura S, Nochajski P, Gao L, Sotomayor P, Matsui S, Gelman IH. Cell Cycle. Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12.2010 Dec 1; 9(23):4656-65. Epub 2010 Dec 1. PMCID: PMC3048035
  • Albain KS, Barlow WE, Ravdin PM…Levine EG, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374(9707):2055-63. PMCID: PMC3140679
  • Almyroudis NG, Fabian J, Hahn T, Segal BH, Wetzler M, McCarthy Jr PL. Late infectious complications after cord blood stem cell transplantation. European journal of clinical microbiology and infectious diseases 2009; 2811:1405-1408 PMID:19672638
  • Almyroudis NG, Wetzler M, McCarthy PL Jr, Wang ES, Wongkittiroch K, Hazamy PA, Samonis G, Hahn T, Lesse AJ, Segal BH. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infection control and hospital epidemiology 2011; 325:490-496 PMID: 21515980
  • Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM. Acute lymphoblastic leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 107:858-914 PMID: 22773801
  • Bansal H, Bansal S, Rao M…Lee KP, et al. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood 2010; 116(22):4591-9. PMCID: PMC2996117
  • Becker H, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Powell BL, Wu Y-Z, Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, Whitman SP, Paschka P, Holland KB, Bloomfield CD. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 1165:788-792 PMCID: PMC2918333
  • Becker H, Larson RA, Caligiuri MA, Baer MR, Carroll AJ, Wetzler M, Kolitz JE, Carter TH, Powell BL, Paschka P, Schwind S, Wu Y-Z, Whitman SP, Margeson D, Mrozek K, Radmacher MD, Maharry K, Marcucci G, Bloomfield CD. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of clinical oncology 2010; 284:596-604 PMCID: PMC2815994
  • Becker H, Maharry K, Radmacher MD, Mrozek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica 2011; 9610:1488-1495 PMCID: PMC3186310
  • Becker H, Marcucci G, Maharry K…Wetzler M, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28(4):596-604. PMCID: PMC2815994
  • Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. Journal of clinical oncology 2009; 2726:4422-4432 PMCID: PMC2744278
  • Bistulfi G, Vandette E, Matsui S, Smiraglia DJ. Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells.BMC Biol. 2010 Jan 21; 8:6. PMCID: PMC2845099
  • Brady MT, Lee J, Ferrone S, Wang ES, Wetzler M. Interferon-gamma secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leukemia research 2011; 352:275-277 PMCID: PMC3021772
  • Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. Journal of clinical oncology 2011; 295:487-494 PMID: 21220605
  • Cancer Genome Atlas Research Network Affiliated RPCI Contributors: Koboldt DC, Fulton RS, McLellan MD…Morrison CD, Gaudioso C, et al. Comprehensive molecular portraits of human breast tumors. Nature. 2012; 7418(490): 61-70. PMCID: PMC3465532
  • Cancer Genome Atlas Research Network Affiliated RPCI Contributors: Bell D, Berchuck A, Birrer M…Morrison CD, Gaudioso C, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 7353(474): 609-615. PMCID: PMC3163504
  • Cancer Genome Atlas Research Network Affiliated RPCI Contributors: Koboldt DC, Fulton RS, McLellan MD…Morrison CD, Gaudioso C, et al. Comprehensive molecular portraits of human breast tumors. Nature. 2012; 7418(490): 61-70. PMCID: PMC3465532
  • Cancer Genome Atlas Research Network Affiliated RPCI Contributors: Hammerman PS, Lawrence MS, Voet D…Morrison CD, Gaudioso C, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 7417(489): 519-525. PMCID: PMC3466113
  • Cancer Genome Atlas Research Network Affiliated RPCI Contributors: Bell D, Berchuck A, Birrer M…Morrison CD, Gaudioso C, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 7353(474): 609-615. PMCID: PMC3163504
  • Cortes J, Kantarjian H, Ball ED, DiPersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 2012; 1182:418-427
  • Cortes J, Laadem A, Brown Jr A, Krishnamurthy M, Abboud CN, Pham D, Schiller GJ, Dey BR, Luger S, Matous J, Craig M, Wetzler M, Maziarz RT, Moore JO, Seiter K. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. Journal of clinical oncology 2010; 2827:4207-4213
  • Cortes JE, Albitar M, McDougall K, Salvado A, Saleh M, Kerr R, Burke JM, Akard L, Wetzler M, Giles FJ, Powell BL, Goldberg SL, Kantarjian HM, Radich J. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Journal of clinical oncology 2009; 2728:4754-4759
  • Damodaran S, Bellavia T, Sait SNJ, Wang ES, Wetzler M, Khushalani NI. Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clinical colorectal cancer 2012; 112:151-154
  • Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, Wetzler M, Mashtare T, Wang ES. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leukemia research 2011; 355:579-584
  • Deeb KK, Luo W, Karpf AR, Omilian AR, Bshara W, Tian L, Tangrea MA, Morrison CD, Johnson CS, Trump DL. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics 2011; 6(8):994-1000. PMCID: PMC3219083
  • Deeb KK, Luo W, Karpf AR, Omilian AR, Bshara W, Tian L, Tangrea MA, Morrison CD, Johnson CS, Trump DL. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics 2011; 6(8):994-1000. PMCID: PMC3219083
  • Drake AS, Brady MT, Wang XH, Sait SJN, Earp JC, Ghoshal S, Ferrone S, Wang ES, Wetzler M. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer immunology, immunotherapy : CII 2009; 583:415-427
  • Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012; 30(6):637-43. PMCID: PMC3295561
  • Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrozek K, Whitman SP, Metzeler KH, Mendler JH, Wu Y-Z, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, De La Chapelle A, Bloomfield CD. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 2012; 1202:249-258
  • Faderl S, O'Brien S, Pui C-H, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010; 1165:1165-1176
  • Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. Journal of clinical oncology 2012; 3020:2492-2499
  • Francis J, Spangenthal E, Cohen IL, McCarthy PL, Smiley S, Paplham P, Wang E, Wetzler M, Ahluwalia MS, Battiwalla M. Reversible cardiotoxicity with tyrosine kinase inhibitors. Clinical advances in hematology and oncology : H&O 2010; 82:128-132
  • Ghoshal Gupta S, Baumann H, Wetzler M. Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia. Leukemia research 2008; 327:1005-1014
  • Ghoshal S, Rao I, Earp JC, Jusko WJ, Wetzler M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer chemotherapy and pharmacology 2010; 664:681-689
  • Hampras SS, Ford L, Blanco JG, Chennamaneni R, Wetzler M, Singh PK, Zirpoli G, Baer MR, Weiss J, Sucheston L, Moysich KB. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with acute myeloid leukemia. International journal of molecular epidemiology and genetics 2010; 13:201-207
  • Harb A, Tan W, Wilding GE, Battiwalla M, Sait SNJ, Wang ES, Wetzler M. Acute myeloid leukemia and diabetes insipidus with monosomy 7. Cancer genetics and cytogenetics 2009; 1902:97-100
  • Harb AJ, Wang ES, Wallace PK, Barcos M, Block AW, Sait SNJ, Ford L, Wilding GE, Tan W, Wetzler M. Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. Cancer 2009; 11511:2472-2481
  • Jarkowski A 3rd, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, Wang ES, Wetzler M. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. Journal of oncology pharmacy practice 2012; 181:91-96
  • Kuptsova-Clarkson N, Wetzler M, Blanco J, Ford L, Kopecky KJ, Zirpoli G, Sucheston LE, Baer MR, Weiss J, Ambrosone CB, Moysich KB. XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia. International journal of molecular epidemiology and genetics 2010; 14:278-294
  • Lal D , Fetterly GJ , Wetzler M , Prey J , Murphy M , Mashtare TJ , Tian L , Lin M-H , Perez AM , Marinaro J Demock K , Park JA , Wang ES. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Molecular cancer therapeutics 2010; 910:2737-2751
  • Lee HJ, Licht AS, Hyland AJ, Ford LA, Sait SN, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Is obesity a prognostic factor for acute myeloid leukemia outcome?. Annals of hematology 2012; 913:359-365
  • Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011; 1178:1583-1594
  • Liu C, Morishima M, Yu T, Matsui SI, Zhang L, Fu D, Pao A, Costa AC, Gardiner KJ, Cowell JK, Nowak NJ, Parmacek MS, Liang P, Baldini A, Yu YE. Genetic analysis of Down syndrome-associated heart defects in mice. Hum Genet. 2011 Apr 10. PMCID: PMC3257027
  • Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 2010; 70(14):5953-5962. PMCID: PMC2928678
  • Marcucci G, Maharry K, Wu YZ…Wetzler M, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28(14):2348-55. PMCID: PMC2881719
  • Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. Journal of clinical oncology 2012; 307:742-750
  • Marcucci G, Metzeler KH, Schwind S…Wetzler M, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30(7):742-50 PMCID: PMC3295550
  • Marcucci G, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Metzeler KH, Schwind S, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Bloomfield CD. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology 2010; 2814:2348-2355
  • Marella NV, Malyavantham KS, Wang J, Matsui S, Liang P, Berezney R. Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. Cancer Res. 2009 Jul 15; 69(14):5946-53. Epub 2009 Jul 7. Erratum in: Cancer Res. 2009 Oct 1; 69(19):7894. PMCID: PMC2826242
  • Marella NV, Zeitz MJ, Malyavantham KS, Pliss A, Matsui S, Goetze S, Bode J, Raska I, Berezney R. Ladder-like amplification of the type I interferon gene cluster in the human osteosarcoma cell line MG63. Chromosome Res. 2008; 16(8):1177-92. Epub 2008 Nov 15. PMCID: PMC2990676
  • Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD . RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. Journal of clinical oncology 2012; 3025:3109-3118
  • Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, Nicolet D, Whitman SP, Wu Y-Z, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 11826:6920-6929
  • Metzeler KH, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Powell BL, Blum W, Wu YZ, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Bloomfield CD. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology 2011; 2910:1373-1381
  • Metzeler KH, Maharry K, Radmacher MD…Wetzler M, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 201; 29(10):1373-81. PMCID: PMC3084003
  • Noor SJ, Wang ES, Thompson JE, Block AW, Sait SN, Barcos M, Ford LA, Wilding GE, Tan W, Wetzler M. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leukemia research 2011; 355:608-613
  • Nowak NJ, Wang ES, Wallace PK, Ford L, Liu S, Gaile D, Deeb G, Zeidan A, Sait SNJ, Wetzler M. Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer genetics and cytogenetics 2010; 1991:15-20
  • Nowak NJ, Wetzler M, Ford LA, Starostik P, Mashtare T, Gold D, Sait SNJ, Wang ES, Deeb G. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer genetics and cytogenetics 2010; 2022:101-107
  • O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VVB, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F. Chronic myelogenous leukemia. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 101:64-110
  • O'Brien S, Pinilla-Ibarz J, Radich JP, Shah NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Mughal T, Moore JO, Berman E, Borghaei H, DeAngelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Wetzler M. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 79:984-1023
  • O'Brien S, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M, Radich JP, Przepiorka D, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, National Comprehensive Cancer Network. Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2007; 55:474-496
  • Odunsi K, Matsuzaki J, Karbach J…Morrison CD, Lele S, Shrikant P, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012; 109(15):5797-802. PMCID: PMC3326498
  • Radich JP, Wetzler M, Sundar HM, Snyder DS, Smith BD, Houldsworth J, Horning SJ, Erba HP, Czuczman MS, Croce CM, Chan WC, Zelenetz AD, Winter JN. NCCN task force report: molecular markers in leukemias and lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7 Suppl. 4:S1-S34, quiz S35-S36
  • Rossi MR, Laduca J, Cowell JK, Srivastava BI, Matsui S. Genomic analysis of CD8+ NK/T cell line, 'SRIK-NKL', with array-based CGH (aCGH), SKY/FISH and molecular mapping. Leuk Res. 2008 Mar;32(3):455-63. Epub 2007 Jul 20. PMCID: PMC2855542
  • Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases. Annals of oncology 2008; 199:1634-1638
  • Tallman MS, Wetzler M, Rowe JM, Perez WS, Pedersen T, Mehta J, Litzow MR, Lazarus HM, Keating A, Logan BR, Gandham S, Dewald GW, Weisdorf DJ. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007; 1101:409-417
  • Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M. Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling. Leukemia research 2012; 3611:1410-1416
  • Varadarajan R, Cummings MK, Hyland AJ, Wang ES, Wetzler M. Can decreasing smoking prevalence reduce leukemia mortality?. Annals of hematology 2010; 899:873-876
  • Varadarajan R, Ford L, Sait SNJ, Block AW, Barcos M, Wallace PK, Ramnath N, Wang ES, Wetzler M. Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer. Leukemia research 2009; 339:1208-1211
  • Varadarajan R, Licht AS, Hyland AJ, Ford LA, Sait SNJ, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Smoking adversely affects survival in acute myeloid leukemia patients. International journal of cancer 2012; 1306:1451-1458
  • Vigil CE, Griffiths EA, Wang ES, Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood reviews 2011; 253:139-146
  • Wetzler M, Segal D. Omacetaxine as an Anticancer Therapeutic: What is Old is New Again. Current pharmaceutical design 2011; 171:59-64
  • Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H. Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 2011; 11721:4861-4868
  • Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leukemia and lymphoma 2008; 497:1274-1278
  • Wetzler M, Earp JC, Brady MT, Keng MK, Jusko WJ. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling. Clinical cancer research 2007; 137:2261-2270
  • Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007; 10910:4164-4167
  • Whitman SP , Carter TH , Kolitz JE , Wetzler M , Moore JO , Stone RM , Carroll AJ , Larson RA , Caligiuri MA , Marcucci G , Powell BL , Baer MR , Wen J , Maharry K , Radmacher MD , Becker H , Mrozek K , Margeson D , Holland KB , Wu Y-Z , Schwind S , Metzeler KH , Bloomfield CD . FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 11618:3622-3626
  • Yu T, Clapcote SJ, Li Z, Liu C, Pao A, Bechard AR, Carattini-Rivera S, Matsui S, Roder JC, Baldini A, Mobley WC, Bradley A, Yu YE. Deficiencies in the region syntenic to human 21q22.3 cause cognitive deficits in mice. Mamm Genome. 2010 Jun; 21(5-6):258-67. Epub 2010 May 29. PMCID: PMC3023176
  • Yu T, Li Z, Jia Z, Clapcote SJ, Liu C, Li S, Asrar S, Pao A, Chen R, Fan N, Carattini-Rivera S, Bechard AR, Spring S, Henkelman RM, Stoica G, Matsui S, Nowak NJ, Roder JC, Chen C, Bradley A, Yu YE. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet. 2010 Jul 15; 19(14):2780-91. Epub 2010 May 4. PMCID: PMC2893810
  • Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand?. Expert opinion on biological therapy 2009; 91:111-119
  • Zeidan A, Wang ES, Wetzler M. What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response. Clinical advances in hematology and oncology : H&O 2008; 69:673-683
  • Zientek-Targosz H, Kunnev D, Hawthorn L, Venkov M, Matsui S, Cheney RT, Ionov Y. Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: a model for identifying candidate breast-tumor suppressors. Mol Cancer. 2008 Jun 5; 7:51. PMCID: PMC2430587